Back to research

Research paper

The expanding field of genetic developmental and epileptic encephalopathies

Lancet review of the expanding genetic landscape in DEEs. Covers gene discovery rates, emerging mosaic detection methods, and therapeutic implications (gene-specific therapies where available).

Indexed context

Specchio N, et al.

deesgenetic-landscapemosaicismgene-specific-therapylancetreview

Markdown path

content/research/papers/2024-specchio-expanding-genetic-dees-lancet.md

Findings

Lancet review of the expanding genetic landscape in DEEs. Covers gene discovery rates, emerging mosaic detection methods, and therapeutic implications (gene-specific therapies where available).

Why it may matter for Levi

Supports the rationale for re-analysis / tissue-based sequencing in Levi given his three negative germline workups - the genetic landscape has moved since his last analysis. Reinforces existing top diagnostic priority (mosaic-sensitive tissue-based PROS panel). Companion to the Freibauer 2023 and Mirzaa 2014 records already in the corpus.

Paper text

Specchio et al. (2024) — Expanding field of genetic DEEs

Source

  • Lancet Child & Adolescent Health, 2024.

Why in corpus

Review of the expanding genetic architecture of DEEs, cited in the 2026 DEE-SWAS comprehensive review as background for the PI3K-AKT-mTOR / overgrowth / autism / epilepsy triad framing.

Key findings

  • Catalogs growing number of genes implicated in DEEs, including mTOR-axis genes (PTEN, TSC1/2, MTOR, PIK3CA, AKT, STRADA) and channelopathy, synaptic, and chromatin genes.
  • Emphasizes overlap between DEE, ASD, and overgrowth in mTOR-axis disorders.

Levi-relevant takeaways

  • Background framing for Levi's top differential hypothesis (mosaic PI3K-AKT-mTOR) — consistent with the broader field's recognition of mTOR-axis disorders as a large and growing share of genetic DEEs with overgrowth.
  • Reinforces the diagnostics priority on mosaic-sensitive tissue-based PI3K-AKT-mTOR panels.
  • No new direct treatment implication.